{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T10:18:10Z","timestamp":1760955490943},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1097\/cnd.0000000000000029","type":"journal-article","created":{"date-parts":[[2014,5,27]],"date-time":"2014-05-27T02:36:33Z","timestamp":1401158193000},"page":"152-156","source":"Crossref","is-referenced-by-count":6,"title":["Sixty Six\u2013Month Follow-up of Muscle Power and Respiratory Function in a Case With Adult-Type Pompe Disease Treated With Enzyme Replacement Therapy"],"prefix":"10.1097","volume":"15","author":[{"given":"Reina","family":"Isayama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensuke","family":"Shiga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuya","family":"Seo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumiko","family":"Azuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasukiyo","family":"Araki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ai","family":"Hamano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hedesato","family":"Takezawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nagato","family":"Kuriyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuo","family":"Takezawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiki","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-3-20210126","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.nmd.2008.11.007","article-title":". Rate of disease progression during long-term follow-up of patients with late-onset Pompe disease.","volume":"19","author":"Van der Beek","year":"2009","journal-title":"Neuromuscul Disord"},{"key":"R3-3-20210126","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","article-title":". Recombinant human acid alpha-glucosidase: Major clinical benefits in infantile-onset Pompe disease.","volume":"68","author":"Kishnani","year":"2007","journal-title":"Neurology"},{"key":"R4-3-20210126","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1542\/peds.113.5.e448","article-title":". Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk.","volume":"113","author":"Van den Hout","year":"2004","journal-title":"Pediatrics"},{"key":"R5-3-20210126","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00415-005-0922-9","article-title":". The natural course of non-classic Pompes disease; a review of 225 published cases.","volume":"252","author":"Winkel","year":"2005","journal-title":"J Neurol"},{"key":"R6-3-20210126","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1750-1172-6-34","article-title":". Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy.","volume":"6","author":"Gungor","year":"2011","journal-title":"Orphanet J Rare Dis"},{"key":"R8-3-20210126","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1164\/ajrccm.166.1.at1102","article-title":"ATS statement: Guidelines for the six-minute walk test.","volume":"166","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"R9-3-20210126","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/mus.1053","article-title":"Physiological alterations of maximal voluntary quadriceps activation by changes of knee joint angle.","volume":"24","author":"Becker","year":"2001","journal-title":"Muscle Nerve"},{"key":"R10-3-20210126","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1007\/s00415-011-6293-5","article-title":". Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years.","volume":"259","author":"Angelini","year":"2012","journal-title":"J Neurol"},{"key":"R11-3-20210126","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1750-1172-7-73","article-title":". Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: An open-label single-center study.","volume":"7","author":"de Vries","year":"2012","journal-title":"Orphanet J Rare Dis"},{"key":"R12-3-20210126","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1212\/WNL.0b013e31818da93f","article-title":". Management and treatment of glycogenosis type II.","volume":"71","author":"Bembi","year":"2008","journal-title":"Neurology"},{"key":"R13-3-20210126","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/mus.21025","article-title":". Clinical features of late-onset Pompe disease: A prospective cohort study.","volume":"38","author":"Wokke","year":"2008","journal-title":"Muscle Nerve"},{"key":"R14-3-20210126","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s10545-011-9393-6","article-title":". Effects of enzyme replacement therapy on five patients with advanced late-onset glycogen storage disease type II: A 2-year follow-up study.","volume":"35","author":"Furusawa","year":"2012","journal-title":"J Inherit Metab Dis"},{"key":"R15-3-20210126","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ymgme.2012.04.027","article-title":". The impact of antibodies in late-onset Pompe disease: A case series and literature review.","volume":"106","author":"Patel","year":"2012","journal-title":"Mol Genet Metab"},{"key":"R16-3-20210126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta16390","article-title":". The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: A longitudinal cohort study of people with lysosomal storage disorders.","volume":"16","author":"Wyatt","year":"2012","journal-title":"Health Technol Assess"},{"key":"R17-3-20210126","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11910-011-0236-5","article-title":"Enzyme replacement therapy for Pompe disease.","volume":"12","author":"Angelini","year":"2012","journal-title":"Curr Neurol Neurosci Rep"}],"container-title":["Journal of Clinical Neuromuscular Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CND.0000000000000029","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T20:24:42Z","timestamp":1621887882000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00131402-201406000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/cnd.0000000000000029","relation":{},"ISSN":["1522-0443"],"issn-type":[{"value":"1522-0443","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]}}}